Journal
NEUROSCIENTIST
Volume 20, Issue 4, Pages 372-386Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1073858413516800
Keywords
Nogo-A; CNS; development; disease; spinal cord injury; stroke; ALS; Alzheimer's; schizophrenia; multiple sclerosis
Categories
Funding
- European Union
- Swiss National Science Foundation [310030B_138676/1]
- European Research Council (ERC) [294115-NOGORISE]
- Swiss National Science Foundation (SNF) [310030B_138676] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Initially discovered as a potent neurite outgrowth inhibitor in the central nervous system (CNS), Nogo-A has emerged as a multifunctional protein. Involvement of this protein has been demonstrated in numerous developmental processes, ranging from cell migration, axon guidance and fasciculation, dendritic branching and CNS plasticity to oligodendrocyte differentiation and myelination. Although initially necessary and beneficial for shaping and later maintaining CNS structure and functionality, the growth restricting properties of Nogo-A can have negative effects on nervous system injury or disease. Hence, correlating with its various neurobiological roles, Nogo-A was implicated in a range of CNS disturbances, including trauma such as spinal cord injury or stroke, neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis or multiple sclerosis, or in schizophrenia. In this review, we summarize the current state of knowledge for Nogo-A's involvement in these nervous system diseases and perturbations and discuss the possible underlying mechanisms. Furthermore, we provide a comprehensive overview on molecular signaling pathways as well as structural properties identified for Nogo-A and point to open questions in the field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available